ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORSMESM..................*JBDM Ver 1.7.2 (20 November 2019) - 2999001/03380468CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120201104W173deBibliographieenBibliographyfrBibliographieEP16801774.72016112520180627enenen20152095920151127GB2020110420204520181003201840202005202020212020031820201104202045C07D 403/14 20060101AFI20170622BHEP A61K 31/501 20060101ALI20170622BHEP A61P 35/00 20060101ALI20170622BHEP deBIS-PYRIDAZIN-VERBINDUNGEN UND DEREN VERWENDUNG IN DER BEHANDLUNG VON KREBSenBIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCERfrCOMPOSÉS DE BIS-PYRIDAZINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCERWO-A1-2015/181539WO-A2-2015/101957FINLAY, Maurice, Raymond, VerschoyleAstraZeneca R&D Cambridge Darwin Building Cambridge Science Park Milton RoadCambridge Cambridgeshire CB4 0FZGBCancer Research Technology Limited1018602432 Redman PlaceLondon E20 1JQGBHGF1018598911 City WalkLeeds LS11 9DXGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRBA20180627ME20180627EP201607889920161125enWO201708958720170601201722